Patient preparation and radiation protection guidance for adult patients undergoing radioiodine treatment for thyroid cancer in the UK
Craig, A. J.
Strachan, M. W. J.
AffiliationWeston Park Cancer Centre, Sheffield, UK
MetadataShow full item record
AbstractRadioactive iodine is a highly effective treatment for thyroid cancer and has now been used in clinical practice for more than 80 years. In general, the treatment is well tolerated. However, it can be logistically quite complex for patients due to the need to reduce iodine intake and achieve high levels of thyroid-stimulating hormone prior to treatment. Radiation protection precautions must also be taken to protect others from unnecessary radiation exposure following treatment. It has been well documented by thyroid cancer patient support groups that there is significant variation in practice across the UK. It is clear that some patients are being asked to observe unnecessarily burdensome restrictions that make it more difficult for them to tolerate the treatment. At the instigation of these support groups, a multidisciplinary group was assembled to examine the evidence and generate guidance on best practice for the preparation of patients for this treatment and the management of subsequent radiation protection precautions, with a focus on personalising the advice given to individual patients. The guidance includes advice about managing particularly challenging situations, for example treating patients who require haemodialysis. We have also worked together to produce a patient information leaflet covering these issues. We hope that the guidance document and patient information leaflet will assist centres in improving our patients' experience of receiving radioactive iodine. The patient information sheet is available as Supplementary Material to this article.
CitationWadsley J, Armstrong N, Bassett-Smith V, Beasley M, Chandler R, Cluny L, et al. Patient Preparation and Radiation Protection Guidance for Adult Patients Undergoing Radioiodine Treatment for Thyroid Cancer in the UK. Clinical oncology (Royal College of Radiologists (Great Britain)). 2022 Aug 24. PubMed PMID: 36030168. Epub 2022/08/28. eng.
- Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
- Authors: Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A
- Issue date: 2012 May 3
- Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid.
- Authors: Barrington SF, Kettle AG, O'Doherty MJ, Wells CP, Somer EJ, Coakley AJ
- Issue date: 1996 Feb
- Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I : practice recommendations of the American Thyroid Association.
- Authors: American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ, Wexler JA, Asamoah E, Avram AM, Milas M, Greenlee C
- Issue date: 2011 Apr
- Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
- Authors: Dehbi HM, Mallick U, Wadsley J, Newbold K, Harmer C, Hackshaw A
- Issue date: 2019 Jan
- Childhood thyroid cancers and radioactive iodine therapy: necessity of precautious radiation health risk management.
- Authors: Kumagai A, Reiners C, Drozd V, Yamashita S
- Issue date: 2007 Dec